Press centre

GARDP Welcomes Funding from Republic and Canton of Geneva to Develop New Gonorrhoea Treatment
14 Sep 2021

GARDP Welcomes Funding from Republic and Canton of Geneva to Develop New Gonorrhoea Treatment

GARDP is pleased to announce funding from the Canton of Geneva to support the development of zoliflodacin, a novel antibiotic currently being assessed through a global phase 3 trial for safety and effectiveness as a treatment for gonorrhoea.

Read more

Media contacts

For media inquiries, please contact the GARDP Communications Department:

Phone: +41 22 555 19 90 | Email: communications@gardp.org

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.